Challenges and Opportunities for Effective Cancer Immunotherapies

doi:10.3390/books978-3-0365-6961-1

Reprint

Download Flyer

Challenges and Opportunities for Effective Cancer Immunotherapies

Edited by

March 2023

500 pages

ISBN978-3-0365-6960-4 (Hardback)
ISBN978-3-0365-6961-1 (PDF)

https://doi.org/10.3390/books978-3-0365-6961-1

Free download (PDF)

This book is a reprint of the Special Issue Challenges and Opportunities for Effective Cancer Immunotherapies that was published in

Biology & Life Sciences

Medicine & Pharmacology

Summary

Anti-cancer immunotherapies have generated spectacular outcomes in the clinical environment and changed treatment schemes for cancer patients. Adoptive cell therapies (ACTs), including using autologous tumor-infiltrating lymphocytes and chimeric antigen receptor (CAR) T cells, and checkpoint blockades have emerged as the most effective treatments for certain cancers. The current challenge for cancer immunotherapies is that although some patients have benefited from the treatments, a number of cancers are resistant. The purpose of this Special Issue is to understand anti-cancer immunotherapy treatment resistance mechanisms and explore new options to provide opportunities for effective treatments.

Format

Hardback

License

Keywords

near infrared photoimmunotherapy; monoclonal antibodies; CD44; interleukin-15; cancer; antigen processing and presentation; cancer immunotherapy; cross-priming; immunogenicity; major histocompatibility complex; T lymphocyte; tumor-infiltrating lymphocytes; tumor microenvironment; tumor-specific antigen; pancreatic tumor; NK cell immunosurveillance; NKG2D; histon (de)acetylation; immunotherapy; PD-1; microenvironment; CAR T cells; immune checkpoint inhibitors; cervical cancer; immune checkpoint inhibitor; pembrolizumab; recurrence; pattern-recognition receptors; toll-like receptors; intratumoural; tumour microenvironment; NKG2D ligands; NKG2D receptor; NK cells; immune evasion; convergent evolution; cancer; viruses; immunotherapy; glioblastoma; immunotherapy; model; animal model; preclinical; murine; immune response; GBM; newcastle disease virus; modulated electrohyperthermia; dendritic cell vaccination; clinical trial; individualized multimodal immunotherapy; CAR-T cell therapy; CD19; clinical trials; CRS; toxicity; immunocyte membrane-coated nanoparticles; biomimicry; cancer immunotherapy; macrophage; T-cell; natural killer; dendritic cell; IL-12 family cytokines; tumor microenvironment; cancer immunotherapy; anti-tumor immunity; STAT; B cell; T cell; antibody therapy; immuno-oncology; CD3-bispecific antibody; T-cell engager; solid tumors; on-target off-tumor toxicity; T-cell co-stimulation; tumor-associated antigens; chimeric antigen receptor; immune cell; endodomain; combination therapy; TNFα; immunotherapy; adoptive cell therapy; monoclonal antibody; immune checkpoint inhibitor; cancer; NK cells; radiotherapy; local ablation therapies; checkpoint inhibitors; chemotherapy; protein kinase inhibitors; oncolytic virus; cancer; anti-cancer therapies; T cell receptor; chimeric antigen receptor (CAR) T cell (CAR-T); signal transduction; CD8 coreceptor; signaling kinetics; oligomerization; TAM receptors; Axl; MerTK; PD-1; small molecule inhibitors; cancer; CAR T cell therapy; T cell metabolism; mitochondria; memory T cell; metabolic reprogramming; adipose tissue-derived stem cells (ADSCs); mesenchymal stem cells; oncolytic virus; myxoma virus; oncolytic virotherapy; pancreatic ductal adenocarcinoma; Flt3; Flt3L; dendritic cells; cancer immunotherapy; HER2-positive; breast cancer; immune checkpoint blockade; immune checkpoint molecules; PD-1/PD-L1; immunotherapy; melanoma; tumour antigens; Ropporin-1; ROPN1; Ropporin-1B; ROPN1B; nonreplicating adenovirus vector; cancer; gene therapy; routes of delivery; virus coated with cancer cell membrane; melanoma; adoptive cell transfer; targeted therapy; cell cycle; immuno-oncology; n/a